India's Generic Wave Slashes Semaglutide Prices by Up to 90%
Following Novo Nordisk's semaglutide patent expiry, at least 15 Indian manufacturers released generic versions within two days, pushing prices down as much as 90%. The rapid launch showcases India's pharmaceutical manufacturing clout and could reshape global diabetes drug pricing.